RNASE3 and granular corneal dystrophy type II: Kim et al. reported that (1) ACD patients who were confirmed with positive patch testing (N = 169) show a significantly higher value of serum ECP than non-ACD patients (N = 47) with negative or irrelevant results (20.6 (12.9–31.3) μg/L vs. 13.3 (6.7–18.3) μg/L; median (25% percentile–75% percentile)) and (2) demographics (sex; occupation; atopic dermatitis comorbidity; location of eczema; age; disease duration; body surface area involvement) and other biomarkers (eosinophil count; IgE) show no significant differences.